Swedish Orphan Biovitrum AB (publ)
BIOVFOTCHealthcare● Active
$47.35
$-0.13(-0.26%)
Market Cap$16.4B
P/E Ratio—
52W High$48
52W Low$27.06
Swedish Orphan Biovitrum AB (publ) (BIOVF) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · BIOVF · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $28.17B | $26.03B | $22.12B | $18.79B | $15.53B |
| Cost of Revenue | $15.88B | $5.79B | $5.00B | $4.78B | $3.48B |
| Gross Profit | $12.29B | $20.24B | $17.13B | $14.01B | $12.04B |
| Gross Margin %(computed) | 43.63% | 77.77% | 77.42% | 74.58% | 77.56% |
| Operating Expenses | |||||
| R&D Expenses | $3.24B | $3.54B | $2.80B | $2.35B | $1.99B |
| G&A Expenses | $11.14B | $7.55B | $10.16B | $7.85B | $6.29B |
| Total Operating Expenses | $4.26B | $14.62B | $13.06B | $10.17B | $8.26B |
| Operating Income | $8.03B | $5.63B | $4.07B | $3.81B | $3.73B |
| Operating Margin %(computed) | 28.50% | 21.61% | 18.38% | 20.29% | 24.04% |
| Interest Income | $0.00B | $0.03B | $0.03B | $0.01B | $0.42B |
| Interest Expense | $0.83B | $1.24B | $1.11B | $0.46B | $0.00B |
| Income Before Tax | $0.03B | $4.41B | $2.95B | $3.32B | $3.29B |
| Income Tax Expense | ($0.44B) | $0.53B | $0.55B | $0.68B | $0.62B |
| Net Income | $0.48B | $3.88B | $2.41B | $2.64B | $2.68B |
| Net Margin %(computed) | 1.69% | 14.93% | 10.89% | 14.04% | 17.25% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $1.39 | $11.37 | $7.39 | $8.52 | $8.67 |
| Wtd Avg Shares | 0.34B | 0.34B | 0.33B | 0.31B | 0.31B |
| EBITDA | $10.94B | $9.30B | $7.23B | $6.05B | $5.72B |
| EBITDA Margin %(computed) | 38.82% | 35.75% | 32.70% | 32.20% | 36.83% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · SEK · B
Explore more Swedish Orphan Biovitrum AB (publ) data
About Swedish Orphan Biovitrum AB (publ) (BIOVF) Income Statement
Swedish Orphan Biovitrum AB (publ) (BIOVF) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, BIOVF reported revenue of $28.17B, gross profit of $12.29B (gross margin 43.63%), and net income of $0.48B — a net profit margin of 1.69%.
Frequently asked questions
BIOVF · 4 questionsSwedish Orphan Biovitrum AB (publ) (BIOVF) reported revenue of $28.17B for 2025, up 8.2% year-over-year.
BIOVF revenueBIOVF salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09